Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life-Reference-Cited by-同舟云学术

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life

Published:2017-10-19 Issue:12 Volume:92 Page:E668-E670
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Breccia Massimo¹^ORCID,Colafigli Gioia¹,Molica Matteo¹,Scalzulli Emilia¹,Diverio Daniela¹,Latagliata Roberto¹^ORCID,Guarini Anna¹,Foà Robin¹

Affiliation:

1. Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1; Sapienza University; Rome Italy

Publisher

Wiley

Subject

Hematology

Reference11 articles.

1. The concept of treatment-free remission in chronic myeloid leukemia;Saussele;Leukemia.,2016

2. Impact of treatment with frontline nilotinib vs imatinib on sustained deep molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase;Hochhaus;Blood.,2015

3. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia;Cross;Leukemia.,2015

4. European LeukemiaNet recommendations for the management of chronic myeloid leukemia;Baccarani;Blood.,2013

5. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study;Hochhaus;Leukemia.,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?;British Journal of Haematology;2023-12-26

2. CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions;Current Hematologic Malignancy Reports;2022-10-20

3. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory;Annals of Hematology;2022-08-30

4. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice;Expert Review of Hematology;2020-12-01

5. Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up;Leukemia & Lymphoma;2020-08-16